Purpose: The current study seeks to investigate the association between lacrimal disorders and the use of docetaxel and paclitaxel.
Methods: A disproportionality analysis was conducted using the United States FDA Adverse Event Reporting System (FAERS). All adverse event reports containing the term docetaxel or paclitaxel were selected.